{"created":"2015-05-14T15:33:47+00:00","modified":"2015-05-14T15:33:47+00:00","valid":{"from":"2015-04-20T21:00:40+00:00","to":"3015-04-20T21:00:40+00:00"},"hreflang":"en","guid":"7c395549-0200-4e73-8890-b6b12ca6f817","contenttemplated":"[{\"content\":\"<p>It’s a great time to own health stocks. <span>In fact, over the past five years, the sector has outperformed most other industries.</span></p>\",\"type\":\"text/html\"},{\"content\":\"<p>[[{&quot;fid&quot;:&quot;288177&quot;,&quot;view_mode&quot;:&quot;default&quot;,&quot;fields&quot;:{&quot;format&quot;:&quot;default&quot;,&quot;field_file_image_alt_text[und][0][value]&quot;:&quot;&quot;,&quot;field_file_image_title_text[und][0][value]&quot;:&quot;&quot;,&quot;field_description[und][0][value]&quot;:&quot;%3Cem%3Evia%20%3Ca%20href%3D%5C%22http%3A%2F%2Fnews.morningstar.com%2FstockReturns%2FCapWtdSectorReturns.html%5C%22%20target%3D%5C%22_blank%5C%22%3EMorningstar%3C%2Fa%3E%3C%2Fem%3E&quot;,&quot;field_description[und][0][format]&quot;:&quot;full_html&quot;,&quot;field_byline_text[und][0][value]&quot;:&quot;&quot;,&quot;field_migration_notes[und][0][value]&quot;:&quot;&quot;},&quot;type&quot;:&quot;media&quot;,&quot;attributes&quot;:{&quot;height&quot;:258,&quot;width&quot;:957,&quot;class&quot;:&quot;media-element file-default&quot;}}]]</p>\",\"type\":\"text/html\"},{\"content\":\"<p>What’s driving the surge? <span>Wunderlich Securities analyst Art Hogan says it’s easy as saying &quot;ACA.&quot;</span></p>\",\"type\":\"text/html\"},{\"content\":\"<p>“Whether you are running a hospital, a doctor practice, a pharmaceutical company, there is more access to your product,” he says of the Affordable Care Act. <span>Thanks to Obamacare, more than 11 million people are newly insured, which means a raft of new customers.</span></p>\",\"type\":\"text/html\"},{\"content\":\"<p>“Therefore, profitability in the healthcare sector is going to go with that,” says Hogan.</p>\",\"type\":\"text/html\"},{\"content\":\"<p>The health care law is just one source of success. <span>Biotech firms are on fire, with saying those companies are up 18 percent this year, more than doubling the total sector. </span><span>Bloomberg Intelligence Healthcare analyst Asthika Goonewardene says firms are developing innovative products.</span></p>\",\"type\":\"text/html\"},{\"content\":\"<p>“We are going through a phase where the science is very, very good. I don’t want to say you are guaranteed clinical success, but your chance of clinical success are really high,” he says.</p>\",\"type\":\"text/html\"},{\"content\":\"<p>Goonewardene points to Gilead’s highly effective hepatitis C treatment Sovaldi, which has generated more than $10 billion in revenue. <span>A drug that helps patients, no doubt, but at $1,000 a pill, it’s expensive. </span><span>It’s an issue that dogs big biotech blockbuster drugs.</span></p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>“The question that comes to mind is, &apos;Okay, you are having all these great drugs come out. Who is going to pay for them?&apos;”</p>\"},{\"type\":\"text/html\",\"content\":\"<p>That’s the big risk with these hot biotech firms. <span>As a rule, Goonewardene says pricing questions send stock prices fluttering. </span><span>And as companies likely deliver more powerful drugs, these questions will only intensify.</span></p>\"}]","byline":"D Gorenstein","itags":["Marketplace for Monday, April 20, 2015","Marketplace","PMP:Marketplace_PMP","7c3955490200e7398904b6b12ca6f817"],"teaser":"More people are insured, and biotechs are doing well, too.","description":"More people are insured, and biotechs are doing well, too.","contentencoded":"<div class=\"barn-cleaned\"><p>It’s a great time to own health stocks.&nbsp;<span>In fact, over the past five years, the sector has outperformed most other industries.</span></p>\n<p>[[{\"fid\":\"288177\",\"view_mode\":\"default\",\"fields\":{\"format\":\"default\",\"field_file_image_alt_text[und][0][value]\":\"\",\"field_file_image_title_text[und][0][value]\":\"\",\"field_description[und][0][value]\":\"%3Cem%3Evia%20%3Ca%20href%3D%5C%22http%3A%2F%2Fnews.morningstar.com%2FstockReturns%2FCapWtdSectorReturns.html%5C%22%20target%3D%5C%22_blank%5C%22%3EMorningstar%3C%2Fa%3E%3C%2Fem%3E\",\"field_description[und][0][format]\":\"full_html\",\"field_byline_text[und][0][value]\":\"\",\"field_migration_notes[und][0][value]\":\"\"},\"type\":\"media\",\"attributes\":{\"height\":258,\"width\":957,\"class\":\"media-element file-default\"}}]]</p>\n<p>What’s driving the surge?&nbsp;<span>Wunderlich Securities analyst Art Hogan says it’s easy as saying \"ACA.\"</span></p>\n<p>“Whether you are running a hospital, a doctor practice, a pharmaceutical company, there is more access to your product,” he says of the Affordable Care Act.&nbsp;<span>Thanks to Obamacare, more than 11 million people are newly insured, which means a raft of new customers.</span></p>\n<p>“Therefore, profitability in the healthcare sector is going to go with that,” says Hogan.</p>\n<p>The health care law is just one source of success.&nbsp;<span>Biotech firms are on fire, with saying those companies are up 18 percent this year, more than doubling the total sector.&nbsp;</span><span>Bloomberg Intelligence Healthcare analyst Asthika Goonewardene says firms are developing innovative products.</span></p>\n<p>“We are going through a phase where the science is very, very good. I don’t want to say you are guaranteed clinical success, but your chance of clinical success are really high,” he says.</p>\n<p>Goonewardene points to Gilead’s highly effective hepatitis C treatment Sovaldi, which has generated more than $10 billion in revenue.&nbsp;<span>A drug that helps patients, no doubt, but at $1,000 a pill, it’s expensive.&nbsp;</span><span>It’s an issue that dogs big biotech blockbuster drugs.</span></p>\n<p>“The question that comes to mind is, 'Okay, you are having all these great drugs come out. Who is going to pay for them?'”</p>\n<p>That’s the big risk with these hot biotech firms.&nbsp;<span>As a rule, Goonewardene says pricing questions send stock prices fluttering.&nbsp;</span><span>And as companies likely deliver more powerful drugs, these questions will only intensify.</span></p></div>","tags":["Health Care","ACA","APM","pharmaceuticals","health stocks"],"published":"2015-04-20T21:00:40+00:00","title":"Why health stocks are doing so well","audio":[{"type":"image/jpeg","meta":{"width":"610","height":"340","crop":"primary"},"href":"http://www.marketplace.org/sites/default/files/styles/primary-image-610x340/public/495314721_2.jpg?itok=2xLLV4ME"},{"meta":{"duration":112,"duration_hms":"00:01:52","api":{"href":"http://api.publicradio.org/audio/v2?ref=pmp&id=apm-audio:/marketplace/segments/2015/04/20/mp_20150420_seg_19","type":"application/json"}},"format":"MP3","type":"audio/mpeg","href":"http://play.publicradio.org/pmp/d/podcast/marketplace/segments/2015/04/20/mp_20150420_seg_19_64.mp3"}]}